$0.85
▲ +2.7% Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial
Overview
52-week range
$0.33
$1.51
44% of range
Avg surprise (last 3)
+9.3%
Avg reaction (last 2)
-0.9%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.08 | $-0.05 | -60.0% | -33.3% | 0.0% | earnings |
| Fri Aug 8, 2025 | Jun/2025 | $-0.05 | $-0.11 | +54.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.06 | $-0.09 | +33.3% | — | -1.9% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Aug 14, 2026 | Jun/2026 | OTHER | -$0.06 | -$0.05 | -20.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-9M | — | $-5M |
| Net income | $-9M | — | $-5M |
| EPS (diluted) | $-0.08 | — | $-0.06 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $5M | $5M | — |
| Inventory | — | — | — |
| Total current assets | $7M | $7M | — |
| Total assets | $8M | $8M | — |
| Long-term debt | — | — | — |
| Total liabilities | $13M | $11M | — |
| Total equity | $-5M | $-4M | $4M |
Implied volatility — last 90 days
No IV snapshots yet for ONCY.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.